FY2025 · ended Dec 31, 2025 · Revenue $8.32B, +0.9% YoY · Filed Feb 27, 2026
Solventum Corporation (SOLV) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $8.3 billion and net income of $1.6 billion. Free cash flow was -$10.0 million. As of Jun 30, 2026 it held $403.0 million in cash and investments and $5.3 billion in total debt.
Revenue (TTM)
$8.31B
-0.9% vs year-ago TTM
Net income (TTM)
$1.43B
+277.4% vs year-ago TTM
Operating cash flow (TTM)
$209.00M
-64.3% vs year-ago TTM
Free cash flow (TTM)
$-118.00M
-180.3% vs year-ago TTM
EPS (TTM)
$8.19
+276.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
173.49M
+0.3% vs prior year
Net cash
$-4.88B
as of Jun 30, 2026
Operating margin
25.0%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- SOLV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Eagan, MN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1964738
- Former names
- 3M Health Care Co (until Feb 9, 2024)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $8.3B | $8.3B |
| Operating income | $2.2B | $1.0B |
| Net income | $1.6B | $479.0M |
| Diluted EPS | $8.88 | $2.76 |
| Operating cash flow | $369.0M | $1.2B |
| Free cash flow | -$10.0M | $805.0M |
| Total assets | $14.3B | $14.5B |
| Total liabilities | $9.2B | $11.5B |
| Stockholders' equity | $5.0B | $3.0B |
| Cash and investments | $878.0M | $762.0M |
| Total debt | $5.2B | $8.2B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 20, 2026 | Jul 16, 2026 |
| 8-K |
Current report
Other events
|
Jun 5, 2026 | Jun 2, 2026 |
| 8-K |
Current report
Officer or director change
|
May 27, 2026 | May 21, 2026 |
All 261 Solventum Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.